# BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026

- Source: PR Newswire
- Published: 2026-10-23T11:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-present-preclinical-data-demonstrating-synergy-of-glix1-with-parp-inhibitors-in-hr-proficient-ovarian-cancer-at-esmo-2026-302917934.html
- Canonical: https://groundlevelnews.com/story/biolinerx-and-hemispherian-present-preclinical-data-demonstrating-syne-dca1b5/

GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand the efficacy of PARP inhibitors In an HR-proficient ovarian cancer patient-derived...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._